GENMAB A/S -SP ADR (GMAB) Stock Price, Quote, News and Summary
NASDAQ:GMAB - Nasdaq - US3723032062 - ADR
GMAB Quote and Key Statistics
GENMAB A/S -SP ADR
NASDAQ:GMAB (1/21/2025, 8:03:41 PM)
After market: 21.76 -0.04 (-0.18%)21.8
+1 (+4.81%)
GMAB Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.01% | ||
| ROA | 14.25% | ||
| ROE | 17.77% | ||
| Debt/Equity | 0.03 |
GMAB Performance and Technical Analysis
GMAB Ownership and Analysts
GMAB Latest News and Analysis
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
For those who appreciate value investing, GENMAB A/S -SP ADR (NASDAQ:GMAB) is a compelling option with its solid fundamentals.
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.
About GMAB
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
GENMAB A/S -SP ADR
Carl Jacobsens Vej 30
Valby 1560 DK
CEO: Jan G. J. van de Winkel
Employees: 2526
Company Website: https://www.genmab.com/
Investor Relations: https://www.genmab.com/investors
Phone: 4570202728
GMAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |